Literature DB >> 24229495

Gender-specific association of the SLC6A4 and DRD2 gene variants in bipolar disorder.

Tzu-Yun Wang1, Sheng-Yu Lee1, Shiou-Lan Chen2, Yun-Hsuan Chang2, Shih-Heng Chen3, San-Yuan Huang4, Nian-Sheng Tzeng4, Chen-Lin Wang2, Pin-Hsi Yeh1, Kao Chin Chen1, I Hui Lee1, Tzung Lieh Yeh1, Yen Kuang Yang1, Ru-Band Lu1.   

Abstract

Findings on the association between the risk for developing bipolar disorder and the functions of the serotonin transporter-linked polymorphic region gene (5-HTTLPR) and dopamine D2 receptor gene (DRD2) variants are contradictory. One explanation for this is that a gender difference may exist for genetic contributions. We compared the gender-related main effects and the gene-to-gene interaction between serotonin transporter gene (SLC6A4) and DRD2 in adult male and female patients with bipolar I (BP-I) and bipolar II (BP-II) disorder. Patients with BP-I (n = 400) and BP-II (n = 493), and healthy controls (n = 442) were recruited from Taiwan's Han Chinese population. The genotypes of the 5-HTTLPR and DRD2 Taq-IA polymorphisms were determined using polymerase chain reaction-restriction fragment length polymorphism analysis. Logistic regression analysis showed a significant gender-specific association of the DRD2 A1/A1 and the 5-HTTLPR S/S, S/LG , and LG/LG (S+) (p = 0.01) genotypes in men with BP-I (p = 0.002 and 0.01, respectively) and BP-II (p = 0.001 and 0.007, respectively), but not in women. A significant interaction for the DRD2 A1/A1 and 5-HTTLPR S+ polymorphisms was also found only in men with BP-I and BP-II (p = 0.003 and 0.001, respectively). We provide preliminary evidence for a gender-specific effect of the SLC6A4 and DRD2 gene variants for the risk of BP-I and of BP-II. We also found gender-specific interaction between 5-HTTLPR and DRD2 Taq-IA polymorphisms in patients with bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24229495     DOI: 10.1017/S1461145713001296

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  6 in total

1.  Serotonin transporter gene polymorphism (5-HTTLPR) influences trait anxiety by modulating the functional connectivity between the amygdala and insula in Han Chinese males.

Authors:  Lin Zhang; Ling Liu; Xueting Li; Yiying Song; Jia Liu
Journal:  Hum Brain Mapp       Date:  2015-04-02       Impact factor: 5.038

Review 2.  Perspective on Etiology and Treatment of Bipolar Disorders in China: Clinical Implications and Future Directions.

Authors:  Zuowei Wang; Chen Jun; Keming Gao; Haichen Yang; Yiru Fang
Journal:  Neurosci Bull       Date:  2019-05-16       Impact factor: 5.203

Review 3.  Application of Research Domain Criteria to childhood and adolescent impulsive and addictive disorders: Implications for treatment.

Authors:  Sarah W Yip; Marc N Potenza
Journal:  Clin Psychol Rev       Date:  2016-11-09

4.  Sex-specific pathways among tri-allelic serotonin transporter polymorphism, trait neuroticism and generalized anxiety disorder.

Authors:  Hsin-An Chang; Wen-Hui Fang; Yia-Ping Liu; Nian-Sheng Tzeng; Jia-Fwu Shyu; Fang-Jung Wan; San-Yuan Huang; Tieh-Ching Chang; Chuan-Chia Chang
Journal:  J Psychiatry Neurosci       Date:  2020-11-01       Impact factor: 6.186

5.  The genome-wide associated candidate gene ZNF804A and psychosis-proneness: Evidence of sex-modulated association.

Authors:  Marta de Castro-Catala; Aurea Mora-Solano; Thomas R Kwapil; Paula Cristóbal-Narváez; Tamara Sheinbaum; Anna Racioppi; Neus Barrantes-Vidal; Araceli Rosa
Journal:  PLoS One       Date:  2017-09-20       Impact factor: 3.240

6.  Identification of Susceptible Loci and Enriched Pathways for Bipolar II Disorder Using Genome-Wide Association Studies.

Authors:  Chung-Feng Kao; Hui-Wen Chen; Hsi-Chung Chen; Jenn-Hwai Yang; Ming-Chyi Huang; Yi-Hang Chiu; Shih-Ku Lin; Ya-Chin Lee; Chih-Min Liu; Li-Chung Chuang; Chien-Hsiun Chen; Jer-Yuarn Wu; Ru-Band Lu; Po-Hsiu Kuo
Journal:  Int J Neuropsychopharmacol       Date:  2016-12-03       Impact factor: 5.176

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.